Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney Disease

NCT05914909 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Interstitial Lung Disease
Chronic Kidney Diseases

Interventions

BIOLOGICAL: AD-214
OTHER: Placebo

Sponsor

AdAlta Limited